Find Funding Opportunities

The purpose of this Notice is to inform potential applicants that NHLBI has provided additional information regarding the allocation of our collaborating ICs' funding contribution to the total budget forRFA-HL-23-015"(New Epidemiological Cohort Study among Asian Americans, Native Hawaiians, and Pacific Islanders (AsA-NHPI): Clinical/Community Field Centers (UG3/UH3)".

The purpose of this notice is to inform applicants of a change to the title to reflect NINR's participation in PAR-22-181 "NIDA, NIMH, NINR and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)".

This Notice informs potential applicants of the National Eye Institute's (NEI) participation in the funding opportunity announcement (FOA) PAR-22-181, NIDA, NIMH, NINR, and NINDS Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional).

The purpose of this notice is to inform applicants of a correction to section III. Eligibility Information for RFA-NS-22-038 "Research Program Award (R35 Clinical Trial Optional)".

This Notice announces an update to the NINDS Special Council Review (SCR) policy. The Notice: (1) aligns the NINDS policy with updated NIH Other Support disclosure requirements (see NOT-OD-21-169) and (2) increases the SCR threshold from $1.0 million in direct costs per year to $2.0 million in total costs (inclusive of direct and indirect costs), per year. This threshold does not represent a cap on NINDS funding and includes only active NIH awards.

The purpose of this notice is to inform applicants of a correction to section III. Eligibility Information for RFA-NS-22-038 "Research Program Award (R35 Clinical Trial Optional)".

This notice alerts applicants about an upcoming Pre-Application and Technical Assistance Webinar for RFA-MH-22-240 on September 22, 2022.

The purpose of this notice is to inform applicants of a clarification/change to the award project period for and the PHS 398 Research Plan for RFA-NS-21-010 "HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional).

The purpose of this notice is to clarify which Funding Opportunity Announcements (FOAs) NINDS will use to solicit applications in response to NOT-ES-22-006 "Notice of Special Interest (NOSI): Climate Change and Health". As stated in the NOSI, NINDS will accept applications from the following announcements: PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required), PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed), PA-20-196 NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required), PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed).

The Office of Research Quality at the National Institute of Neurological Disorders and Stroke (NINDS) is issuing this notice to inform the extramural research community about updates to its initiative to develop an educational resource on the principles of rigorous research. The first set of applications have been funded from the Materials to Enhance Training in Experimental Rigor (METER) (UE5 Clinical Trial Not Allowed) funding opportunity, and two more receipt dates remain: October 11, 2022 and October 10, 2023. Because the mission of this initiative is to develop educational units on a variety of principles of rigorous research, NINDS would like to inform the scientific community about principles of rigorous research that remain high priority for potential development into educational units by METER applicants.